The short version of incretin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-22 and is reviewed periodically as new material appears.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
A subarachnoid hemorrhage is acute bleeding under the arachnoid; it may occur spontaneously or as a result of trauma. A subdural hematoma (SDH) is an extracerebral collection of blood located in the potential space that can separate arachnoid from the dura mater. The origin is usually venous, caused by injury to the bridging veins that connect the dura mater and the arachnoid. Once these are torn, blood leaks into this area. SDHs occur in about 30% cases of severe head trauma. An epidural hematoma (EDH) is a collection of blood between the skull and the dura mater, underlying a bare bone surface. It is often associated with skull fracture. EDH may be arterial (caused by injury of a meningeal artery) or venous (related to damage to of a dural venous sinus or bleeding from diploic veins).
== Description == The cap ranges from 5–15 centimetres (2–6 in) in width and is usually yellow with brownish areas, particularly at the centre. The skin layer covering the cap is sticky and can be peeled off. The yellow stem is 4–10 cm long and 1–2 cm wide, and brownish at the base. The gills are also yellow and the spores are white, producing a white spore print.
Later that day, Afghan Taliban officials announced that they had launched a new wave of attacks against Pakistani border guards in the border areas of Khost and Paktia provinces. The fighting later spread to the border areas of Kunar and Nangarhar provinces. The same day, Pakistani Taliban leader Noor Wali Mehsud ordered the group's fighters to intensify and systematically carry out attacks in support of the Afghan Taliban. He also instructed them to post video evidence of their attacks directly on social media without prior permission. Jamaat ul Ahrar, an offshoot of the Pakistani Taliban, also ordered its fighters to intensify attacks in Pakistan in response to Pakistani airstrikes against the Afghan Taliban. It also said that its fighters would step up attacks in the provinces of Sindh and Punjab. Following these orders, militant attacks on police stations and outposts were reported in Peshawar, Bannu, Hangu, and Mattani, injuring a police officer and a civilian.
=== Nordic countries === Norway was the first country in the world to outlaw beak trimming in 1974, followed by Finland in 1986 and Sweden in 1988. Beak trimming was subsequently phased out in Denmark in two stages: in 2013 for the enriched cage system and in 2014 for aviary and free range systems.
Neuropeptide S (NPS) is a neuropeptide found in human and mammalian brain, mainly produced by neurons in the amygdala and between Barrington's nucleus and the locus coeruleus, although NPS-responsive neurons extend projections into many other brain areas. NPS binds specifically to a G protein-coupled receptor, NPSR. Animal studies show that NPS suppresses anxiety and appetite, induces wakefulness and hyperactivity, and plays a significant role in the extinction of conditioned fear. It has also been shown to significantly enhance dopamine activity in the mesolimbic pathway, and inhibits motility and increases permeability in neurocrine fashion acting through NO in the myenteric plexus in rats and humans.
Sources: en.wikipedia.org
==== Antagonists ==== Cyclazocine Diprenorphine Levallorphan Nalodeine Nalorphine Naloxone Naltrexone Samidorphan Note that some of the above drugs may actually be very weak partial agonists rather than silent antagonists.
=== 1 April === A court in Kyiv ordered the house arrest of Metropolitan Pavlo (born Petro Lebid) of the Ukrainian Orthodox Church (Moscow Patriarchate) for allegedly supporting the Russian invasion of Ukraine. He was later taken under police custody on 14 July. Russia assumed the presidency of the UN Security Council for the month, a role in which Russia was able to maneuver meetings on Ukraine to portray the US and other Western countries as making false accusations against Russia.
Operation LabScam was a United States government investigation in the 1990s by a seven-member taskforce into laboratory billing fraud resulting in $800 million in fines. Fraudulent billing practices included labs billing Medicare and other government healthcare programs for medically unnecessary tests, upcoded tests, tests that were never conducted, and providing kickbacks to physicians. The following labs were implicated: Damon Clinical Laboratories, SmithKline Beecham Clinical Laboratories (SBCL), Corning Life Sciences, Liberty Testing Laboratory.
=== Pharmacodynamics === Methocinnamox is an opioid receptor antagonist, it works at the μ-opioid receptor. By acting as an antagonist, it binds to the receptor but does not activate it, thus blocking the action of agonists such as heroin and fentanyl. It is a pseudo-irreversible non-competitive antagonist of the μ-opioid receptor and a competitive antagonist of the κ- and δ-opioid receptors. Methocinnamox has affinity values for the opioid receptors of 0.6 nM for the μ-opioid receptor, 2.2 nM for the δ-opioid receptor, and 4.9 nM for the κ-opioid receptor. Hence, it has about 3.7-fold preferential affinity for the μ-opioid receptor over the δ-opioid receptor and about 8.2-fold higher affinity for the μ-opioid receptor over the κ-opioid receptor. The antagonism of the μ-opioid receptor by methocinnamox is not irreversible as the drug does not form a covalent bond with the receptor. This is in contrast to prototypical μ-opioid receptor alkylating agents like β-funaltrexamine and β-chlornaltrexamine. However, in spite of its lack of covalent binding to the μ-opioid receptor, methocinnamox appears to not dissociate from the μ-opioid receptor or dissociates from it extremely slowly. Hence, methocinnamox has been described as a pseudo-irreversible antagonist of the μ-opioid receptor or as a "functionally irreversible" antagonist. The mechanism underlying the pseudo-irreversible antagonism of methocinnamox hasn't been fully elucidated.
Sources: en.wikipedia.org
=== Confirmation bias === Confirmation bias is the tendency for people to be more likely to engage with and believe ideas that confirm their preconceived notions. Mass media is not necessarily the root cause of the public's general misconception or judgment of people experiencing mental illness. It is, however, a way for people to confirm their existing beliefs and biases about mental illnesses.
However, many other acid-fast organisms—such as intestinal coccidia and parasitic helminths of the genus Schistosoma—lack mycolic acids yet display comparable acid-fastness, suggesting that other cell-wall structures, such as cyst walls or egg shells, may provide similar resistance to decolorization. Further histopathologic evidence supports this broader mechanism: in tissue sections, staining intensity is markedly reduced when bacterial cell walls are damaged or when xylene-based deparaffinization is used during specimen processing. A xylene-free, heat-based method has been shown to preserve cell-wall integrity and substantially improve detection of mycobacteria and other acid-fast organisms, particularly when using fluorescent Auramine O staining. Acid-fast organisms are difficult to characterize using standard microbiological techniques, though they can be stained using concentrated dyes, particularly when the staining process is combined with heat. Some, such as Mycobacteria, can be stained with the Gram stain, but they do not take the crystal violet well and thus appear light purple, which can still potentially result in an incorrect gram-negative identification. The most common staining technique used to identify acid-fast bacteria is the Ziehl–Neelsen stain, in which acid-fast species appear bright red against a blue background. Another method is the Kinyoun method, in which bacteria appear red against a green background.
The most common set of catabolic reactions in animals can be separated into three main stages. In the first stage, large organic molecules, such as proteins, polysaccharides or lipids, are digested into their smaller components outside cells. Next, these smaller molecules are taken up by cells and converted to smaller molecules, usually acetyl coenzyme A (acetyl-CoA), which releases some energy. Finally, the acetyl group on acetyl-CoA is oxidized to water and carbon dioxide during the citric acid cycle and electron transport chain, releasing more energy while reducing the coenzyme nicotinamide adenine dinucleotide (NAD+) into NADH.
Opiate withdrawal syndrome effects are associated with the abrupt cessation or reduction of prolonged opiate usage. The manifestation of opiate dependence and abuse relies on a variety of factors, including the opiate's pharmacokinetic properties and the user's predisposition for addiction.
== Mechanism of action == Pegulicianine is non-fluorescent in its intact parent form. However, in breast cancer tissue, where cathepsins and matrix metalloproteinases are overexpressed, it is enzymatically cleaved into two fragments, one of which is fluorescent. Pegulicianine consists of the following four components that are covalently linked to each other:
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.